6CM
ATXI

683 Capital Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

683 Capital Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12
Closed -$131K – 183
2019
Q4 		$131K Buy
+12
New +$83.9K 0.02% 144

Other funds holding ATXI

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

683 Capital Management's ATXI Position: Q1 2020 in Review

683 Capital Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2020, closing a stake of 12 shares — an estimated $131K sold.

683 Capital Management first reported a position in ATXI in Q4 2019 and held it in 1 quarter. The position peaked at $131K in Q4 2019. 19 funds tracked by Wall St. Rank hold ATXI as of Q1 2020.

  • 683 Capital Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • 683 Capital Management sold 12 Avenue Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $131K.
  • 683 Capital Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • 683 Capital Management's Avenue Therapeutics, Inc. Common Stock position peaked at $131K in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.